Bexlosteride

Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride.[1][2] It is selective for the type I isoform of the enzyme.[1] It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed.[3][4]

Bexlosteride

Clinical data
Other names	LY 300502
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name (4aR,10bR)-8-Chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
CAS Number	148905-78-6^N
PubChem CID	166562
ChemSpider	145762^Y
UNII	36X732P4P0
ChEMBL	ChEMBL24955^Y
Chemical and physical data
Formula	C14H16ClNO
Molar mass	249.74 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CN1[C@@H]2CCc3cc(ccc3[C@H]2CCC1=O)Cl
InChI InChI=1S/C14H16ClNO/c1-16-13-6-2-9-8-10(15)3-4-11(9)12(13)5-7-14(16)17/h3-4,8,12-13H,2,5-7H2,1H3/t12-,13-/m1/s1^Y Key:WQBIOEFDDDEARX-CHWSQXEVSA-N^Y
^NY (what is this?)  (verify)

See also

• 5α-Reductase inhibitor

References

1. Chang, Chawnshang (2002). Androgens and androgen receptor : mechanisms, functions, and clinical application. Boston: Kluwer Academic Publishers. ISBN 1-4020-7188-4.
2. Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 978-0-470-19039-5.
3. "Drug Profile: Bexlosteride". Adis Insight.
4. Reaxys entry for bexlosteride: Reaxys Registry Number: 6635310